![]() |
|
|
Vol. 54, Issue 4, 647-654, October 1998
Department of Pharmacology, Cancer Center, University of California, San Diego, La Jolla, California 92093 (C.P.S., N.N., R.H.T.) and Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, 30625 Hannover, Germany (M.P.M.)
| |
Summary |
|---|
|
|
|---|
The human UDP-glucuronosyltransferase (UGT) 1A (UGT1A) locus is regulated in a tissue specific fashion in liver and extrahepatic tissues. Three extrahepatic UGT1A proteins, UGT1A7, UGT1A8, and UGT1A10, have been discovered and are believed to contribute to the diversity of extrahepatic glucuronidation. UGTs eliminate by glucuronidation a broad variety of endobiotic and xenobiotic substrates, which include bilirubin, therapeutic drugs, and carcinogens. Human gastric mucosa represents a primary location of tissue contact with dietary constituents, pharmaceutical drugs, and environmental carcinogens. To study the role and regulation of UGT1A gene products in stomach UGT1A mRNA expression and UGT catalytic activities were investigated in a panel of 14 normal gastric mucosa/adenocarcinoma sample pairs. UGT1A mRNA levels were differentially regulated in stomach, a feature not found in hepatic tissue. Normal gastric epithelium consistently expressed extrahepatic UGT1A7 and UGT1A10. However, polymorphic expression of UGT1A1 (29%), UGT1A3 (21%), and UGT1A6 (36%) was detected. Polymorphic UGT1A regulation was confirmed in adenocarcinoma samples with the additional observation of differential down-regulation of UGT1A1, UGT1A3, UGT1A6, and UGT1A10 and up-regulation of UGT1A7 mRNA. The polymorphic UGT1A regulation in stomach contrasts the homogeneous regulation of UGT1A gene products in human liver. Activity assays demonstrated 2- to 4-fold interindividual differences in UGT activity and qualitative differences between individuals. The polymorphic regulation of UGT1A gene products in gastric tissue may be the biological basis that determines interindividual differences in extrahepatic microsomal drug metabolism.
| |
Introduction |
|---|
|
|
|---|
An
important process of detoxification in human catabolic metabolism is
performed by the UGTs localized in the endoplasmic reticulum. UGTs
catalyze the formation of hydrophilic glucuronides, which facilitates
the elimination of substrates from the body via urine or feces (Dutton
et al., 1980
; Bock et al., 1987
; Mackenzie et al., 1997
). Two families of UGT proteins have been
defined and termed UGT1 and UGT2 (Burchell et al., 1991
).
The UGT2 structural genes are located on chromosome 4 (Monaghan et al., 1992
). In contrast, the human
UGT1A locus is located on chromosome 2, spans >160 kilobase
pairs of DNA, with at least 12 individual first exon cassette sequences
followed by exons 2-5 at the 3' end of the locus (Moghrabi et
al., 1992
; Ritter et al., 1992
; Mackenzie et
al., 1997
). The 5' flanking region of each first exon cassette contains appropriate promoter elements. Transcription of each individual first exon leads to a strategy of exon sharing, combining the first exon sequences with common exons 2-5, a mechanism that can
generate up to nine functional transferases (Mackenzie et al., 1997
). UGT1A proteins eliminate by glucuronidation a broad array of endobiotic and exobiotic substrates, including reactive oxygen
products of bioactivation, carcinogens, therapeutic drugs, complex
phenolic compounds, and the heme synthetic byproduct bilirubin (Ebner
et al., 1993
; Ritter et al., 1991
; Green and
Tephly, 1996
; Mojarrabi et al., 1996
; Kim et al.,
1997
; Strassburg et al., 1998
).
Investigation of UGT1A expression has focused primarily on the liver,
which is considered to be the most important location of human
glucuronidation. From liver RNA, five UGT1A cDNAs have been identified
and cloned (Harding et al., 1988
; Ritter et al., 1991
; Wooster et al., 1991
; Mojarrabi et al.,
1996
). It has been demonstrated that hepatocellular tissue expresses
without interindividual variation UGT1A1, UGT1A3, UGT1A4, UGT1A6, and
UGT1A9 gene transcripts (Strassburg et al., 1997b
). We have
recently characterized the tissue specific regulation of the human
UGT1A locus, which has led to the identification of three
additional UGT1A proteins, selectively expressed in extrahepatic
tissues (Strassburg et al., 1997b
; Strassburg et
al., 1998
). The identification of UGT1A7 expression in gastric
epithelium, UGT1A8 expression in colonic epithelium, and UGT1A10
expression in gastric, biliary, and colonic epithelium but not in
hepatocellular epithelium indicates a complex control of this gene
locus and emphasizes a unique physiological role of glucuronidation in
nonhepatocellular epithelial tissues.
Immediate and prolonged contact with ingested matter requires the
stomach to exercise an effective defense against chemical and
biological influences. The expression of individual UGT1A proteins in
gastric mucosa may determine the stomachs epithelial glucuronidation
capacity and may constitute an important factor for extrahepatic
metabolism and first pass effects (Bock et al., 1987
; Bock
and Lilienblum, 1994
; Strassburg et al., 1997a
; Strassburg et al., 1998
). Therefore, variations in drug efficacy and of
carcinogenic risk between individuals may be the result of
interindividual differences of UGT1A regulation in extrahepatic surface
tissue such as gastric epithelium. Because data on the regulation of the UGT1A locus in human gastric epithelium is scarce, we
examined UGT1A mRNA regulation by quantitative DRT-PCR combined with
UGT activity analysis.
| |
Materials and Methods |
|---|
|
|
|---|
Tissue samples.
Gastric tissue samples were obtained from
six female (mean age 58.67 ± 16.79 years) and eight male German
patients (mean age 56.75 ± 11.68 years) with histologically
confirmed gastric adenocarcinoma undergoing gastrectomy at the
University of Hannover Medical Center, Hannover, Germany. The panel
included 14 tissue sample pairs, each consisting of a sample of tumor
tissue and a sample of healthy gastric mucosa from the same resection
specimen. In each gastric tissue sample the mucosa was dissected from
the underlying muscle layer and only mucosal tissue was used for the
analyses. The normal gastric mucosa samples were microanatomically free
of any detectable concurrent disease such as gastritis,
Helicobacter pylori infection, or dysplasia and were all
sampled from the area of the corpus/antrum junction. The patients did
not receive chemotherapeutic compounds before resection and no drug
therapy of any significance was administered. Patient records indicated
absence of tobacco consumption for at least 6 months before sampling.
Normal liver tissue samples were collected from 16 patients undergoing
hemihepatectomy (n = 14) or liver transplantation
(n = 2) for hepatocellular carcinoma (n = 12, 11 men, one woman, mean age 58.08 ± 10.44 years) or focal nodular hyperplasia (n = 4, four women, mean age
37.25 ± 14.48 years) (Strassburg et al., 1997a
). Tumor
tissue was histologically confirmed and showed no signs of necrosis. In
all instances, normal sampling was performed at the distal resection
margin of the specimen and exhibited no signs of macroscopic
deterioration such as necrosis or any histopathological abnormalities.
All tissue was immediately frozen in liquid nitrogen and stored at
80° until use.
RNA Isolation, cDNA synthesis, and RNA purity analysis.
Tissue was pulverized under liquid nitrogen and immediately lysed in
acidic phenol/guanidinium-isothiocyanate solution (Tripure; Boehringer
Mannheim, Mannheim, Germany) as described previously (Strassburg
et al., 1997b
). RNA Concentrations were determined by
spectrophotometry at 260 and 280 nm. Samples were stored in water at
80° until further analysis.
-actin. The sense primer
5'-GGCGGCACCACCATGTACCCT-3' and the antisense primer
5'-AGGGGCCGGACTCGTCATACT-3' (Strassburg et al., 1997b
-actin gene. PCR with
cDNA led to a 202-bp product, but contamination with genomic DNA
template led to a 312-bp PCR product, which can be clearly
distinguished from the 202-bp cDNA amplification product.
Intact RNA with an A260
nm/A280 nm ratio between 1.5 and 1.9 was isolated from all 14 gastric carcinoma/normal tissue pairs. RNA was visualized in acridine orange-stained agarose gels to exclude
tailing, as an additional quality control. In all samples, the RNA did
not contain contaminating genomic DNA. Tailing was also not observed in
the subsequent Northern blot analyses.
DRT-PCR for UGT1A transcripts.
DRT-PCR of a 487-bp fragment
of the conserved UGT1A exons 2-5 has been described previously in
detail (Strassburg et al., 1997b
). Briefly, coamplification
was carried out for six cycles of PCR synthesis with UGT1A primers at a
concentration of 2 mM. After the addition of
-actin
primers to a concentration of 0.4 mM, cycling was continued
for a total of 32 cycles at 94° for 1 min, 59° for 1 min, and 72°
for 1 min. PCR was preceded by a 3-min incubation of the reaction
mixture at 94° and was followed by a 7-min elongation at 72°.
DRT-PCR products were separated in a 2% agarose gel stained with
ethidium bromide. Polaroid (Cambridge, MA) type 665 positive/negative
film was used to quantify bands separated in 2% agarose using laser
densitometry on a LKB 2222-020 UltroScan XL densitometer (LKB, Bromma,
Sweden). Arbitrary units were calculated relative to
-actin products
according to the following formula: (mean peak area for UGT/mean peak
area for
-actin) × 100 = relative arbitrary units.
Independent and combined linear kinetics for both products during the
amplification process were established as previously described in
detail (Strassburg et al., 1997b
). Statistical
analysis was performed using Student's t test from the
GraphPad Prism software (GraphPad, San Diego, CA).
Exon-1-specific DRT-PCR.
The UGT1A locus predicts
the existence of UGT1A1 and UGT1A3-1A10. UGT1A2, -1A11, and -1A12 do
not have an uninterrupted open reading frame and are therefore
considered to be pseudogenes (Mackenzie et al., 1997
).
DRT-PCR detection of all nine UGT1A transcripts predicted by the human
UGT1A locus was performed using nine exon-1-specific sense
primers and two antisense primers located within exons 2-5 or within a
common portion of the 3' end of the first exons. As already described
elsewhere (Strassburg et al., 1997b
), the primers lead to
RT-PCR products of distinct molecular sizes: UGT1A1, 644 bp; UGT1A3,
483 bp; UGT1A4, 572 bp; UGT1A5, 659 bp; UGT1A6, 562 bp; UGT1A7, 754 bp;
UGT1A8, 514 bp; UGT1A9, 392 bp; and UGT1A10, 478 bp. Briefly,
coamplification of UGT1A first-exon and
-actin sequences was
performed using three cycling protocols: UGT1A1 and UGT1A6: 94° (1 min), 59° (1 min), 72° (1 min); UGT1A3, UGT1A4, UGT1A5: 94° (1 min), 56° (1 min), 72° (1 min); UGT1A7, UGT1A8, UGT1A9, UGT1A10:
94° (1 min), 64° (1 min), 72° (1 min). Each protocol was preceded
by a 3-min incubation of the reaction mixture at 94° and was followed
by a 7-min elongation at 72°. The specificity and kinetics of this
assay have previously been reported (Strassburg et al.,
1997b
). Experiments were performed in duplicate, and controls were
performed without cDNA, primers, or thermophilic polymerase included.
Quantification of products by laser densitometry was performed as
described above.
Isolation of microsomal protein from tumor and normal gastric
tissue.
Approximately 200 mg of tissue was pulverized under liquid
nitrogen, resuspended in 1 ml of buffer (50 mM Tris·HCl,
pH7.4, 10 mM MgCl2) and homogenized
with a Potter-Elvehjem tissue grinder. The tissue homogenate was
centrifuged at 10,000 × g for 5 min at 4° in a
microcentrifuge and the supernatant was collected. The pellet was
resuspended in 0.5 ml of buffer, centrifuged, and the supernatant was
collected. The combined supernatants were centrifuged at 150,000 × g for 60 min at 4° in a TL100 ultracentrifuge (Beckman,
Palo Alto, CA) and the pellet was resuspended in 0.2 ml of buffer.
Protein concentration was determined by the method of Bradford et
al. (1976)
. Microsomal protein was stored at
80°.
UGT enzymatic activity assay.
1-naphthol, 4-nitrophenol,
4-methylumbelliferone, 4-isopropylphenol, octylgallate, estriol,
estrone, naringenin, hyodeoxycholic acid (all from Sigma, St. Louis,
MO), and 8-hydroxy-benzo[
]pyrene were suspended in methanol,
7-hydroxy-benzo[
]pyrene was suspended in acetone (-pyrenes
from National Cancer Institute Chemical Carcinogen Repository, Midwest
Research Institute, Kansas City, MO). Microsomal protein (25 µg) in
reaction buffer (50 mM Tris-Cl, pH 7.6, 10 mM
MgCl2) were incubated in the presence of 0.1 mM UDP-glucuronic acid, 0.08 mg/ml phosphatidylcholine,
0.04 µCi of 14C-labeled glucuronic acid, and
0.1 mM of test substrate for 60 min at 37°. Protein was
precipitated by the addition of ethanol and subsequent centrifugation.
Lyophilized supernatants were resuspended in 50 µl of methanol and
separated by thin layer liquid chromatography with
n-butanol/acetone/acetic acid/water (35:35:10:20%) as the running solvent. The production of 14C-labeled
glucuronides was detected by autoradiography. To determine specific
catalytic activities the 14C-labeled glucuronides
were quantified by liquid scintillation counting and expressed as
picomoles of glucuronide formed per minute per milligram of microsomal
protein.
Western blot analysis.
Hepatic and gastric microsomal
protein (25 µg) were boiled for 90 sec in loading buffer (2% sodium
dodecyl sulfate, 62.5 mmol/liter Tris·HCl, pH 6.8, 10% glycerol, and
0.001% bromphenol blue) with 2%
-mercaptoethanol and separated by
8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis before
electrotransfer onto nitrocellulose membrane. As a control, 15 µg of
baculovirus-expressed UGT1A1 protein (Strassburg et al.,
1996
) was included. Immunodetection was performed according to
previously published protocols (Strassburg et al., 1996
).
UGT1A protein was detected using a rabbit anti-UGT1A antiserum raised
against the peptide SSLHKDRPVEPLDLA located between amino acids 441 and
455 of exon 5 of the constant UGT carboxyl-terminal portion (Strassburg
et al., 1998
). Visualization was achieved with an alkaline
phosphatase conjugated goat anti-human IgG diluted at 1:1000.
| |
Results |
|---|
|
|
|---|
Quantitative variability of gastric UGT1A mRNA regulation.
Total RNA from gastric carcinoma and corresponding normal tissue was
analyzed for the expression of UGT1A transcripts by quantitative DRT-PCR (Fig. 1). A 487-bp fragment from
the UGT1A constant exons 2-5 was amplified by RT-PCR and
quantified relative to a coamplified 202-bp fragment of
-actin, as
shown in Fig. 1. Overall UGT1A expression was lower in gastric tissue
compared with hepatic tissue. Between the 14 samples of gastric
adenocarcinoma and normal gastric epithelium, UGT1A expression was
found to be significantly (p = 0.013)
down-regulated, indicating that a quantitative differential regulation
of UGT1A mRNA exists between hepatic and gastric tissue, but also
between gastric adenocarcinoma tissue and healthy gastric epithelium
(Fig. 2).
|
|
Polymorphic regulation of UGT1A isoform expression in human gastric tissue. First-exon sequences encoded by the UGT1A locus share extensive sequence similarity, with 94% similarity among UGT1A7, UGT1A8, UGT1A9, and UGT1A10. Therefore, a transcript specific DRT-PCR assay was employed, capable of detecting all nine predicted UGT1A transcripts (Fig. 3 and Table 1). Gastric mucosa and carcinoma samples were characterized by a unique UGT1A expression pattern. Analysis of the healthy gastric tissue samples revealed UGT1A7 expression in 12 of the 14 samples, whereas UGT1A10 was expressed in all 14 normal tissue samples (Table 1). In contrast, the expression of UGT1A1 was identified in four samples, UGT1A3 in only three samples, and UGT1A6 in five samples. Sequences of the PCR products were confirmed by dideoxy sequencing. The expression of UGT1A4, UGT1A5, UGT1A8, and UGT1A9 was not detected in any of the tissues. The patterns identified in the healthy gastric tissue specimens were confirmed in the corresponding adenocarcinoma tissue samples. In these samples, UGT1A7 and UGT1A10 were expressed in 13 of 14 samples, UGT1A1 in three of 14 samples, UGT1A3 in one of three samples and UGT1A6 in four of 14 samples, whereas UGT1A4, UGT1A5, UGT1A8, and UGT1A9 were also not detected. These findings indicate a polymorphic expression of UGT1A isoforms in human gastric tissue that is present in both normal epithelium and adenocarcinoma tissue from the same subject.
|
|
|
Functional polymorphism of UGT catalytic activity in gastric
microsomal protein.
To assess the functional impact of the
observed polymorphic expression of UGT1A gene products in gastric
epithelium, four microsomal protein preparations of normal gastric
tissue samples expressing different UGT1A transcript patterns were
analyzed (Table 2). In Table 2, sample 1 expressed Fig. 3, pattern C, sample 2 expressed pattern B, sample 3 expressed pattern D, and sample 4 expressed pattern A. Microsomal
glucuronidation activities were examined with a panel of nine
substrates ranging from planar and complex phenols to steroid hormones,
flavones, bile acid metabolites, and hydroxylated benzo[
]pyrene.
Interindividual glucuronidation activity levels varied up to 4-fold
among the four tissue protein samples (1-naphthol, 4-nitrophenol,
4-methylumbelliferone), which is in agreement with the quantitative
differences found at the transcript level (Fig. 2). Sample 3 displayed
the highest level of 1-naphthol, 4-nitrophenol, 4-methylumbelliferone,
and 4-isopropylphenol glucuronidation. On the mRNA level, this sample
is characterized by an abundant expression of UGT1A7 (compare DRT-PCR
analysis of this sample in Fig. 4D). This result is in agreement with
the recently described specific activities of UGT1A7 that favor
phenolic substrates (Strassburg et al., 1998
).
Interestingly, hyodeoxycholic acid, which has been described as a
substrate of UGT2B4 (Jackson et al., 1987
; Fournel-Gigleux
et al., 1991
) and has not been found to be glucuronidated by
UGT1 proteins was glucuronidated by one of the four samples (Table 2,
sample 1). Taken together, these data provide evidence for the
polymorphic regulation of the human UGT1A locus at the RNA
transcript and functional levels, in addition to demonstrating that
UGT2B proteins are potentially regulated in a polymorphic fashion in
human gastric tissue.
|
Detection of UGT1A protein in gastric microsomal fractions. Overall UGT1A protein was detected with an antibody directed against a 15-mer epitope within exon 5 of the common UGT1A carboxyl-terminal portion. Normal liver microsomal protein was compared with a pair of gastric adenocarcinoma/normal gastric mucosa microsomes. In agreement with the observed differences of UGT1A isoform mRNA expression detected by DRT-PCR between the two tissues, band mobility was unique to each tissue type (Fig. 5, lanes 3-5). In addition, the analysis of pairs of adenocarcinoma and normal gastric mucosa tissue demonstrated lower levels of overall UGT1A protein in the adenocarcinoma samples. This finding is in agreement with the results obtained by DRT-PCR on the mRNA level (Fig. 1 and Fig. 2) indicating that down-regulation of UGT1A mRNA leads to down-regulation of UGT1A protein in these samples.
|
| |
Discussion |
|---|
|
|
|---|
Human UGT1A genes are regulated in a tissue-specific
fashion in hepatic and extrahepatic tissue (Strassburg et
al., 1997a
; Strassburg et al., 1998
). This distribution
of individual UGT1A isoforms is believed to determine tissue specific
metabolic and detoxification requirements. Although most UGT1A cDNAs
have been cloned and characterized using hepatic tissue (Harding
et al., 1988
; Ritter et al., 1991
; Wooster
et al., 1991
; Mojarrabi et al., 1996
), the
regulation and function of extrahepatic UGTs is less well established.
As an organ of the digestive tract characterized by prolonged and
immediate contact to dietary constituents, including xenobiotics,
carcinogens, and therapeutic drugs, human gastric epithelium is likely
to play a significant role in extrahepatic detoxification (Peters
et al., 1989
; McDonnell et al., 1996
). Previous
studies have identified UGT1A1 and UGT1A4 expression in the
extrahepatic gastrointestinal tract (McDonnell et al., 1996
)
in addition to significant bilirubin UGT activity in small intestine
(Peters et al., 1989
).
In the present study, we provide evidence for a polymorphic regulation
of the UGT1A locus in gastric mucosa and carcinoma. In a
panel of 14 normal gastric epithelium/adenocarcinoma tissue sample
pairs that were examined, UGT1A7 was expressed in 13 and UGT1A10 was
expressed in all samples, confirming UGT1A7 and UGT1A10 expression as
the predominant extrahepatic UGT1A gene products in human gastric
tissue (Strassburg et al., 1997b
). However, in contrast to
findings obtained with a panel of hepatic tissue samples, gastric
tissue was not characterized by a uniform presence of UGT1A gene
products consistent among individuals. Analysis of the overall UGT1A
mRNA in gastric epithelium displayed significant interindividual
differences. In addition, the expression of UGT1A1 mRNA was observed in
four of 14 samples, UGT1A3 mRNA in three of 14 samples, and UGT1A6 mRNA
in five of 14 samples. This finding documents a polymorphic expression
of the UGT1A locus within a single tissue type. Because the
history of the sampled subjects indicates no relevant drug or nicotine
use, and all samples were obtained from the area of the corpus/antrum
junction, these findings are not likely to be the result of sampling or
external factors. In addition to examining normal gastric epithelium,
corresponding specimens of adenocarcinoma tissue from the same organ
were analyzed for UGT1A mRNA expression. The polymorphic expression of
UGT1A mRNAs was confirmed. Moreover, differential down-regulation of UGT1A1, UGT1A3, UGT1A6, and UGT1A10 was observed in the tumor specimens. Interestingly, UGT1A7 mRNA was up-regulated in gastric adenocarcinoma.
The results also demonstrate that in normal gastric epithelium and paired adenocarcinoma samples, there occurs significant differential regulation of UGT1A gene products. This regulation includes the consistent expression of predominant and tissue-specific UGT1A gene products such as UGT1A7 and UGT1A10, the variable coexpression of individual UGT1A genes such as UGT1A1, UGT1A3, and UGT1A6 in selected individuals, as well as down-regulation and up-regulation of UGT1A gene expression in the course of neoplastic transformation to gastric adenocarcinoma. Combined, the data provides compelling evidence for individual regulation of the human UGT1A gene products in gastric tissue.
Metabolism by glucuronidation in human gastric tissue may therefore be
determined by a regulatory polymorphism that may potentially represent
the molecular biological basis of interindividual differences in
gastric UGT activity. These differences could impact on interindividual rates of glucuronidation of drugs that could potentially be absorbed through the gastrointestinal lining. With few exceptions, all drugs can
be classified as uncharged drugs, organic acids, or organic amines. In
an acidic environment such as that of the stomach, amines would exist
predominately as ionized and protonated molecules that are not readily
accessible for transport into the gastric epithelium. It is interesting
to note that UGT1A4, which has specificity toward the metabolism of
tertiary amines to form quaternary ammonium glucuronides (Green and
Tephly, 1996
), is not expressed in gastric epithelium. However, other
agents, such as weak acids, would be protonated, uncharged, and would
have a high oil/water partition coefficient, allowing for efficient
absorption, thus serving as excellent candidates for glucuronidation in
the stomach. The interindividual variation observed with the expression
of UGT1A1, UGT1A3, UGT1A6, UGT1A7, and UGT1A10 could potentially impact
on drug disposition as a result of variations in first-pass metabolism
through the gastric mucosa. The variations observed in stomach are in
contrast to the consistent UGT1A mRNA regulation in human liver
(Strassburg et al., 1997a
), which further highlights the
differences between hepatic and extrahepatic regulation of the
UGT1A locus.
The polymorphic regulation of a group of xenobiotic and drug
metabolizing enzymes is an interesting finding in view of the stomach's physiological role as a first site of prolonged immediate contact with exobiotic compounds. These differences could potentially modify the cellular defense potential of the stomach against diet-borne cytotoxic and mutagenic compounds, thereby affecting gastric cancer predisposition (Kim et al., 1997
; Strassburg et
al., 1997a
). The analysis of the catalytic ability of gastric
microsomal protein to glucuronidate different substrates was exploited
to further elucidate a functional impact of the discovered polymorphic
regulation. In normal gastric microsomal samples, a 2- to 4-fold
difference in specific activities was noted. In particular, phenolic
4-nitrophenol, 4-methylumbelliferone, and 1-naphthol UGT activities
catalyzed by UGT1A proteins (Ebner et al., 1993
; Ebner and
Burchell et al., 1993
; Green and Tephly, 1996
; Burchell and
Brierley 1998
; Strassburg et al., 1998
), were highly
variable. The considerable overlap of specific substrate activities of
the majority of UGT1A proteins prevents an exact assignment of specific
activity to an individual UGT1A isoform when several UGT1A proteins are
simultaneously expressed in a tissue. This is exemplified by the
substrate estrone, which has been found to be glucuronidated by UGT1A3
(Mojarrabi et al., 1996
) and UGT1A10 (Strassburg et
al., 1998
). Because expression of both isoforms was demonstrated
in gastric tissue in this study, their individual contribution to
microsomal estrone activity cannot be estimated by catalytic activity
assays using microsomal protein preparations. However, the activity of
UGT1A7, which has been found to be uniquely expressed in stomach, was
found to be associated with higher specific activities for phenolics
such as 1-naphthol, 4-methylumbelliferone, and 4-nitrophenol (Fig. 4D;
Table 2, sample 3), all of which have recently been identified as
preferred substrates of UGT1A7 (Strassburg et al., 1998
).
The panel included the putative tobacco carcinogen metabolite
7-hydroxy-benzo[
]pyrene (Strassburg et al., 1998
),
which was also glucuronidated with specific activities that varied
4-fold. This may contribute to interindividual differences in
cytoprotection and genoprotection. Interestingly, a qualitative differential activity was demonstrated for the glucuronidation of
hyodeoxycholic acid. Because hyodeoxycholic acid has not been identified as a substrate for the UGT1A gene products but has been
found to be conjugated by UGT2B4 (Fournel-Gigleux et al., 1991
), the polymorphic patterns of catalytic activities detected here
are very likely to include UGT2B proteins.
The findings presented in this study differ from the classical genetic
polymorphisms of drug metabolizing enzymes, which have been documented
for such cytochrome P450 enzymes as CYP2D6, as well as glutathione
S-transferase, N-acetyltransferases, and
methyltransferases (Daly, 1995
; Meyer and Zanger, 1997
). Most genetic
polymorphisms have been discovered as a result of bifunctional
distribution of drug metabolizing enzyme function, which becomes
clinically evident in adverse drug reactions. The genetic basis of this
feature is the presence of monogenic traits in the normal
population, which is represented as two phenotypes. As a result, drug
metabolizing enzyme function can be substantially altered by homozygous
combination of "loss of function alleles" or enhanced by
duplication or amplification events. Other than in the investigation of
Crigler Najjar's and Gilbert's diseases (Mackenzie et al.,
1997
) genetic polymorphisms have not been documented for the majority
of UGT proteins. We report here a differing observation leading to
polymorphic expression of UGT1A gene product levels and
isoform expression, not following a bimodal distribution. This seems to
be the result of tissue-specific polymorphic regulation of the human
UGT1A gene locus in gastric tumor as well as in normal
gastric epithelium. In contrast to the homogeneous expression of
UGT1A gene products in human hepatic tissue, this also
implies that interindividual regulatory mechanisms may affect the
function of drug metabolizing enzymes in the stomach and thus determine
interindividual variations in metabolism.
In summary, a quantitative and qualitative polymorphism of UGT1A gene regulation in human gastric epithelium has been demonstrated. Interindividual differences in UGT activity included a 4-fold quantitative variation and the qualitative variations of specific substrate activities. The regulation of UGT1A transcripts in gastric tissue follows a complex mode different from that in liver, which may indicate a unique control of human extrahepatic glucuronidation.
| |
Acknowledgments |
|---|
We wish to thank the late Professor R. Pichlmayr, as well as Dr. J. Jähne, Dr. R. Raab and Dr. J. Klempnauer, Department of Abdominal and Transplant Surgery, Medizinische Hochschule Hannover, for their support in tissue sample procurement.
| |
Footnotes |
|---|
Received May 13, 1998; Accepted July 2, 1998
This work was supported by United States Public Health Service Grant GM49135 (R.H.T.) and Deutsche Forschungs Gemeinschaft Grant STR493/2-1 (C.P.S.). C.P.S. is a recipient of the Pete Lopiccola Award in Cancer Research, University of California, San Diego.
Send reprint requests to: Robert H. Tukey, Ph.D., Department of Pharmacology, UCSD Cancer Center, BSB 4th Floor, Rm 4021, 9500 Gilman Dr., La Jolla, CA 92093-0636. E-mail: rtukey{at}ucsd.edu
| |
Abbreviations |
|---|
UGT, UDP-glucuronosyltransferase; DRT-PCR, duplex reverse transcription polymerase chain reaction; bp, base pair(s).
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al. PhRMA White Paper on ADME Pharmacogenomics J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nguyen, J. A. Bonzo, S. Chen, S. Chouinard, M. J. Kelner, G. Hardiman, A. Belanger, and R. H. Tukey Disruption of the Ugt1 Locus in Mice Resembles Human Crigler-Najjar Type I Disease J. Biol. Chem., March 21, 2008; 283(12): 7901 - 7911. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. B. Buckley and C. D. Klaassen Tissue- and Gender-Specific mRNA Expression of UDP-Glucuronosyltransferases (UGTs) in Mice Drug Metab. Dispos., January 1, 2007; 35(1): 121 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. Gardner-Stephen and P. I. Mackenzie Isolation of the UDP-Glucuronosyltransferase 1A3 and 1A4 Proximal Promoters and Characterization of Their Dependence on the Transcription Factor Hepatocyte Nuclear Factor 1{alpha} Drug Metab. Dispos., January 1, 2007; 35(1): 116 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. I. Loureiro, M. J. Bonifacio, C. Fernandes-Lopes, L. Almeida, L. C. Wright, and P. Soares-Da-Silva Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation Drug Metab. Dispos., November 1, 2006; 34(11): 1856 - 1862. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Innocenti, E. E. Vokes, and M. J. Ratain Irinogenetics: What Is the Right Star? J. Clin. Oncol., May 20, 2006; 24(15): 2221 - 2224. [Full Text] [PDF] |
||||
![]() |
J.-F. Gagnon, O. Bernard, L. Villeneuve, B. Tetu, and C. Guillemette Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer Clin. Cancer Res., March 15, 2006; 12(6): 1850 - 1858. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chen, D. Beaton, N. Nguyen, K. Senekeo-Effenberger, E. Brace-Sinnokrak, U. Argikar, R. P. Remmel, J. Trottier, O. Barbier, J. K. Ritter, et al. Tissue-specific, Inducible, and Hormonal Control of the Human UDP-Glucuronosyltransferase-1 (UGT1) Locus J. Biol. Chem., November 11, 2005; 280(45): 37547 - 37557. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. O. Lankisch, A. Vogel, S. Eilermann, A. Fiebeler, B. Krone, A. Barut, M. P. Manns, and C. P. Strassburg Identification and Characterization of a Functional TATA Box Polymorphism of the UDP Glucuronosyltransferase 1A7 Gene Mol. Pharmacol., May 1, 2005; 67(5): 1732 - 1739. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Liu, F. Innocenti, M. J. Ratain, N. Kato, Y. Wang, and M. Omata Linkage Disequilibrium across the UGT1A Locus Should Not Be Ignored in Association Studies of Cancer Susceptibility Clin. Cancer Res., February 1, 2005; 11(3): 1348 - 1349. [Full Text] [PDF] |
||||
![]() |
M. Michael and M.M. Doherty Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Martineau, A. Tchernof, and A. Belanger AMINO ACID RESIDUE ILE211 IS ESSENTIAL FOR THE ENZYMATIC ACTIVITY OF HUMAN UDP-GLUCURONOSYLTRANSFERASE 1A10 (UGT1A10) Drug Metab. Dispos., April 1, 2004; 32(4): 455 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Gregory, R. H. Lewinsky, D. A. Gardner-Stephen, and P. I. Mackenzie Coordinate Regulation of the Human UDP-Glucuronosyltransferase 1A8, 1A9, and 1A10 Genes by Hepatocyte Nuclear Factor 1{alpha} and the Caudal-Related Homeodomain Protein 2 Mol. Pharmacol., April 1, 2004; 65(4): 953 - 963. [Abstract] [Full Text] |
||||
![]() |
P. G. Wells, P. I. Mackenzie, J. Roy Chowdhury, C. Guillemette, P. A. Gregory, Y. Ishii, A. J. Hansen, F. K. Kessler, P. M. Kim, N. Roy Chowdhury, et al. GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE Drug Metab. Dispos., March 1, 2004; 32(3): 281 - 290. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-L. Fang and P. Lazarus Correlation between the UDP-Glucuronosyltransferase (UGT1A1) TATAA Box Polymorphism and Carcinogen Detoxification Phenotype: Significantly Decreased Glucuronidating Activity against Benzo(a)pyrene-7,8-dihydrodiol(-) in Liver Microsomes from Subjects with the UGT1A1*28 Variant Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 102 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Gregory, D. A. Gardner-Stephen, R. H. Lewinsky, K. N. Duncliffe, and P. I. Mackenzie Cloning and Characterization of the Human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 Gene Promoters: |